Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA1991/000378external-prioritypatent/WO1992007871A1/en
Application filed by Allelix BiopharmafiledCriticalAllelix Biopharma
Publication of NO931503D0publicationCriticalpatent/NO931503D0/en
Publication of NO931503LpublicationCriticalpatent/NO931503L/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Peptides Or Proteins
(AREA)
Abstract
Oligopeptider anvendelige for å inhibere HIV-replikasjon i virus- infiserte individer. En foretrukket utførelsesform av oligopeptidet er en D-arginin-nonamer med N- og C-terminal- beskyttende grupper, hvilken i en stan- dard analysebestemmelse i en konsentra- sjon på 5 pM, oppviser høyere enn 95% inhibering av HIV-replikasjon.Oligopeptides useful for inhibiting HIV replication in virus-infected individuals. A preferred embodiment of the oligopeptide is a D-arginine nonamer with N- and C-terminal protecting groups, which, in a standard assay at a concentration of 5 µM, exhibits greater than 95% inhibition of HIV replication.
NO93931503A1990-10-241993-04-23
PEPTID-BASED HIV REPLICATION INHIBITORS
NO931503L
(en)